Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 6/2019

Open Access 01-08-2019 | Original Paper

Health state utilities associated with post-surgical Staphylococcus aureus infections

Authors: Louis S. Matza, Katherine J. Kim, Holly Yu, Katherine A. Belden, Antonia F. Chen, Mark Kurd, Bruce Y. Lee, Jason Webb

Published in: The European Journal of Health Economics | Issue 6/2019

Login to get access

Abstract

Introduction

Surgical site infections (SSIs) are among the most common and potentially serious complications after surgery. Staphylococcus aureus is a virulent pathogen frequently identified as a cause of SSI. As vaccines and other infection control measures are developed to reduce SSI risk, cost-utility analyses (CUA) of these interventions are needed to inform resource allocation decisions. A recent systematic review found that available SSI utilities are of “questionable quality.” Therefore, the purpose of this study was to estimate the disutility (i.e., utility decrease) associated with SSIs.

Methods

In time trade-off interviews, general population participants in the UK (London, Edinburgh) valued health states drafted based on literature and clinician interviews. Health states described either joint or spine surgery, with or without an SSI. The utility difference between otherwise identical health states with and without the SSI represented the disutility associated with the SSI.

Results

A total of 201 participants completed interviews (50.2% female; mean age = 46.2 years). Mean (SD) utilities of health states describing joint and spine surgery without infections were 0.79 (0.23) and 0.78 (0.23). Disutilities of SSIs ranged from − 0.03 to − 0.32, depending on severity of the infection and subsequent medical interventions. All differences between corresponding health with and without SSIs were statistically significant (all p < 0.001).

Conclusion

The preference-based SSI disutilities derived in this study may be used to represent mild and serious SSIs in CUAs assessing and comparing the value of vaccinations that may reduce the risk of SSIs.
Appendix
Available only for authorised users
Literature
1.
Humphreys, H., Becker, K., Dohmen, P.M., Petrosillo, N., Spencer, M., van Rijen, M., et al.: Staphylococcus aureus and surgical site infections: benefits of screening and decolonization before surgery. J. Hosp. Infect. 94(3), 295–304 (2016)CrossRefPubMed
2.
Kane, T., Carothers, K., Lee, S.: Virulence factor targeting of the bacterial pathogen Staphylococcus aureus for vaccine and therapeutics. Curr. Drug Targets. 19(2), 111–127 (2016)CrossRef
3.
Giersing, B.K., Dastgheyb, S.S., Modjarrad, K., Moorthy, V.: Status of vaccine research and development of vaccines for Staphylococcus aureus. Vaccine. 34(26), 2962–2966 (2016)CrossRefPubMed
4.
Noskin, G.A., Rubin, R.J., Schentag, J.J., Kluytmans, J., Hedblom, E.C., Jacobson, C., et al.: National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin. Infect. Dis. 45(9), 1132–1140 (2007)CrossRefPubMed
5.
Patel, H., Khoury, H., Girgenti, D., Welner, S., Yu, H.: Burden of Surgical Site Infections Associated with Arthroplasty and the Contribution of Staphylococcus aureus. Surg. Infect. (Larchmt) 17(1), 78–88 (2016)CrossRef
6.
7.
Creech, C.B., Frenck, R.W., Sheldon, E.A., Seiden, D.J., Kankam, M.K., Zito, E.T., et al.: Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. Vaccine. 35(2), 385–394 (2017)CrossRefPubMed
8.
Frenck, R.W., Creech, C.B., Sheldon, E.A., Seiden, D.J., Kankam, M.K., Baber, J., et al.: Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine 35(2), 375–384 (2017)CrossRefPubMed
9.
Lee, B.Y., Wiringa, A.E., Bailey, R.R., Lewis, G.J., Feura, J., Muder, R.R.: Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis. Vaccine. 28(12), 2465–2471 (2010)CrossRefPubMedPubMedCentral
10.
Torrance, G.W.: Measurement of health state utilities for economic appraisal. J. Health Econ. 5(1), 1–30 (1986)CrossRefPubMed
11.
Torrance, G.W.: Preferences for health outcomes and cost-utility analysis. Am. J. Manag. Care 8–20 (1997)
12.
Brazier, J.R., Ratcliffe, J., Salomon, J.A., Tsuchiya, A.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, New York (2007)
13.
Feeny, D.: Preference-based measures: utility and quality-adjusted life years. In: Fayers, P., Hays, R. (eds.) Assessing quality of life in clinical trials, 2nd edn., pp. 405–431. Oxford University Press, New York (2005)
14.
Gheorghe, A., Moran, G., Duffy, H., Roberts, T., Pinkney, T., Calvert, M.: Health utility values associated with surgical site infection: a systematic review. Value Health. 18(8), 1126–1137 (2015)CrossRefPubMed
15.
Bailey, R.R., Stuckey, D.R., Norman, B.A., Duggan, A.P., Bacon, K.M., Connor, D.L., et al.: Economic value of dispensing home-based preoperative chlorhexidine bathing cloths to prevent surgical site infection. Infect. Control Hosp. Epidemiol. 32(5), 465–471 (2011)CrossRefPubMedPubMedCentral
16.
Courville, X.F., Tomek, I.M., Kirkland, K.B., Birhle, M., Kantor, S.R., Finlayson, S.R.: Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis. Infect. Control Hosp. Epidemiol. 33(2), 152–159 (2012)CrossRefPubMed
17.
Cranny, G., Elliott, R., Weatherly, H., Chambers, D., Hawkins, N., Myers, L., et al.: A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health Technol. Assess. 12(1), iii-iv (2008)CrossRef
18.
Cummins, J.S., Tomek, I.M., Kantor, S.R., Furnes, O., Engesaeter, L.B., Finlayson, S.R.: Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. J. Bone Joint Surg. Am. 91(3), 634–641 (2009)CrossRefPubMed
19.
Slover, J., Espehaug, B., Havelin, L.I., Engesaeter, L.B., Furnes, O., Tomek, I., et al.: Cost-effectiveness of unicompartmental and total knee arthroplasty in elderly low-demand patients. A Markov decision analysis. J. Bone Joint Surg. Am. 88(11), 2348–2355 (2006)CrossRefPubMed
20.
Gu, N.Y., Wolf, C., Leopold, S., Manner, P.A., Doctor, J.N.: A comparison of physician and patient time trade-offs for postoperative hip outcomes. Value Health. 12(4), 618–620 (2009)CrossRefPubMed
21.
Cahill, J.L., Shadbolt, B., Scarvell, J.M., Smith, P.N.: Quality of life after infection in total joint replacement. J. Orthop. Surg. (Hong Kong) 16(1), 58–65 (2008)CrossRef
22.
Lee, B.Y., Wiringa, A.E., Bailey, R.R., Goyal, V., Tsui, B., Lewis, G.J., et al.: The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 31(11), 1130–1138 (2010)CrossRefPubMedPubMedCentral
23.
Marinelli, M., Soccetti, A., Panfoli, N., de Palma, L.: Cost-effectiveness of cemented versus cementless total hip arthroplasty. A Markov decision analysis based on implant cost. J. Orthop. Traumatol. 9(1), 23–28 (2008)CrossRefPubMedPubMedCentral
24.
Fryback, D.G., Dasbach, E.J., Klein, R., Klein, B.E., Dorn, N., Peterson, K., et al.: The beaver dam health outcomes study: initial catalog of health-state quality factors. Med. Decis. Making. 13(2), 89–102 (1993)CrossRefPubMed
25.
Sackett, D.L., Torrance, G.W.: The utility of different health states as perceived by the general public. J Chron Dis. 31(11), 697–704 (1978)CrossRefPubMed
26.
Selai, C., Rosser, R.: Eliciting EuroQol descriptive data and utility scale values from inpatients. A feasibility study. Pharmacoeconomics. 8(2), 147–158 (1995)CrossRefPubMed
27.
Patel, H., Khoury, H., Girgenti, D., Welner, S., Yu, H.: Burden of surgical site infections associated with select spine operations and involvement of Staphylococcus aureus. Surg. Infect. (Larchmt). 18(4), 461–473 (2017)CrossRefPubMedPubMedCentral
28.
Kuppermann, M., Shiboski, S., Feeny, D., Elkin, E.P., Washington, A.E.: Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med. Decis. Making. 17(1), 42–55 (1997)CrossRefPubMed
29.
MacKeigan, L.D., O’Brien, B.J., Oh, P.I.: Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Med. Decis. Making. 19(2), 113–121 (1999)CrossRefPubMed
30.
Matza, L.S., Stewart, K.D., Gandra, S.R., Delio, P.R., Fenster, B.E., Davies, E.W., et al.: Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Serv. Res. 15, 173 (2015)CrossRefPubMedPubMedCentral
31.
32.
33.
34.
35.
36.
37.
38.
39.
Hernigou, P., Flouzat-Lachianette, C.H., Jalil, R., Uirassu Batista, S., Guissou, I., Poignard, A.: Treatment of infected hip arthroplasty. Open Orthop. J. 4, 126–131 (2010)CrossRefPubMedPubMedCentral
40.
41.
Lazennec, J.Y., Fourniols, E., Lenoir, T., Aubry, A., Pissonnier, M.L., Issartel, B., et al.: Infections in the operated spine: update on risk management and therapeutic strategies. Orthop. Traumatol. Surg. Res. 97(6 Suppl), S107–S116 (2011)CrossRefPubMed
42.
Meredith, D.S., Kepler, C.K., Huang, R.C., Brause, B.D., Boachie-Adjei, O.: Postoperative infections of the lumbar spine: presentation and management. Int. Orthop. 36(2), 439–444 (2012)CrossRefPubMed
43.
Scharfenberger, A., Clark, M., Lavoie, G., O’Connor, G., Masson, E., Beaupre, L.A.: Treatment of an infected total hip replacement with the PROSTALAC system. Part 1: Infection resolution. Can. J. Surg. 50(1), 24–28 (2007)PubMedPubMedCentral
44.
Senthi, S., Munro, J.T., Pitto, R.P.: Infection in total hip replacement: meta-analysis. Int. Orthop. 35(2), 253–260 (2011)CrossRefPubMed
45.
Torpy, J.M., Lynm, C., Golub, R.M.: JAMA patient page. Knee replacement. JAMA. 305(8), 844 (2011)PubMed
46.
Johnson, D.P., Bannister, G.C.: The outcome of infected arthroplasty of the knee. J. Bone Joint Surg. Br. 68(2), 289–291 (1986)CrossRefPubMed
47.
Canadian Agency for Drugs and Technologies in Health (CADTH): Guidelines for the economic evaluation of health technologies: Canada [3rd] ed. CAN, Ottawa (2006)
48.
National Institute for Health and Care Excellence (NICE): Process and methods guides: Guide to the methods of technology appraisal 2013. UK; (September 10, London (2013)
49.
Pharmaceutical Benefits Advisory Committee (PBAC): Guidelines for preparing submissions to PBAC, Version 4.3.2. Canberra, Australia; (2008)
50.
Matza, L.S., Sapra, S.J., Dillon, J.F., Kalsekar, A., Davies, E.W., Devine, M.K., et al.: Health state utilities associated with attributes of treatments for hepatitis C. Eur. J. Health Econ. 16(9), 1005–1018 (2015)CrossRefPubMed
51.
Rowen, D., Brazier, J.: Health Utility Measurement. In: Glied, S., Smith, P. (eds.) The Oxford Handbook of Health Economics, pp. 788–813. Oxford University Press, New York (2011)
52.
53.
Matza, L.S., Boye, K.S., Feeny, D.H., Bowman, L., Johnston, J.A., Stewart, K.D., et al.: The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. Eur. J. Health Econ. 17(8), 979–990 (2016)CrossRefPubMed
Metadata
Title
Health state utilities associated with post-surgical Staphylococcus aureus infections
Authors
Louis S. Matza
Katherine J. Kim
Holly Yu
Katherine A. Belden
Antonia F. Chen
Mark Kurd
Bruce Y. Lee
Jason Webb
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 6/2019
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-019-01036-3

Other articles of this Issue 6/2019

The European Journal of Health Economics 6/2019 Go to the issue

Original Paper

Determining preventable acute care spending among high-cost patients in a single-payer public health care system

Original Paper

How to make value-based health insurance designs more effective? A systematic review and meta-analysis

Original Paper

Economic burden of HPV9-related diseases: a real-world cost analysis from Italy

Editorial

Assessing capability in economic evaluation: a life course approach?

Original Paper

Impact of unemployment on self-perceived health

Original Paper

The impact of ambient air pollution on hospital admissions